Printed 12 October 2017
LEO Science & Tech Hub, an R&D unit of LEO Pharma, has signed a cooperation agreement with Cambridge-based biotechnology company Elektrofi to understand more about advanced formulation technology for dermatological drug delivery.
“We are excited to announce this collaboration with Elektrofi to understand more about its innovative Elektroject™ process technology to improve our options in subcutaneous delivery of antibodies,” stated Michael Sierra, Ph.D., VP of LEO Science & Tech Hub.
“Developing therapeutic solutions that aren’t only effective and safe but additionally convenient for patients with skin illnesses is crucial to improving patient experience and outcomes, that is a goal the Hub strives to attain.Inches
Elektrofi leverages a singular therapeutic microparticle suspension system (Elektroject™) to engineer high-concentration, low-viscosity antibody formulations. Even though many antibody formulations become virtually unusable at high concentrations because of high viscosity, Elektroject™ suspensions lead to antibody concentrations which are greater than 15x the typically administered concentration without exceeding viscosity limits.
This permits medical professionals to subcutaneously administer high doses of antibody-based therapies inside a relatively small volume within a few moments.
“We are thinking about creating a paradigm transfer of drug delivery to dramatically enhance the lives of patients,” stated Jason Norris, Co-Founding father of Elektrofi.
“LEO Science & Tech Hub is really a leader in speeding up precision medicine in skin care, and we’re happy to enter this collaboration that will combine Elektrofi’s operate in transforming drug delivery using the Hub’s knowledge of skin care.”
The LEO Science & Tech Hub is acknowledged for its collaborative approach of seeking cutting-edge technology for dermatological applications.
Inside the newbie of their launch, The Hub has effectively created multiple collaborations to understand more about non-invasive biomarker technologies, drug delivery technology, and advanced imaging technology with leading research institutes and biotechnology companies, such as the Karp Lab, Novopyxis, and also the Wellman Center for Photomedicine at Massachusetts General Hospital.
Source: Company Pr Release